Bristol-Myers Squibb has acquired exclusive rights in most world markets to UFT (tegafur and uracil), an anticancer product developed by Taiho Pharmaceutical of Japan.
UFT is an oncology product which in essence can be regarded as an orally-active derivative of 5-fluorouracil, an injectable antimetabolite which is widely used in cancer chemotherapy. The drug is currently marketed in Japan, several Asia-Pacific countries and Spain, and in these countries is indicated for several solid tumor types including colorectal, breast and gastric cancer. It is the best-selling non-hormonal anticancer drug in Japan, largely because of its ease of use.
Under the terms of the agreement, B-MS will conduct Phase III testing of UFT in the USA and Europe, initially for the colorectal indication and later on for other indications. The company gains exclusive marketing rights to the drug in all countries where it is not yet launched.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze